Tag Archives: Atomwise

July 31, 2019
In The News

Mel Yeates from DDNews reports on some of Atomwise’s recent partnerships with Eli Lilly and Enamine.

Read Article
July 23, 2019
In The News

Noah Miller of Newsweek interviews Abraham Heifets, Atomwise CEO, about his Moonshot.

Read Article
July 10, 2019
Press Release

Ann Arbor, Michigan – From making pain management safer and more effective to identifying inhibitors for a fibrosis target protein and more, researchers from Michigan Medicine, as well as the University of Michigan College of Pharmacy and U-M Life Sciences Institute, are looking to advance their projects through Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards […]

Read Article
June 4, 2019
In The News

Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.

Read Article
June 3, 2019
Press Release

Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential […]

Read Article
May 2, 2019
In The News

Originally published on the YC Blog on April 29, 2019. By Jared Friedman In the last 10 years, the tools for studying biology have become much less expensive and more widely available. This has made it possible for new startups to do serious research right from the start, and it is leading to an explosion […]

Read Article